Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT.

The company will offer in-person meeting opportunities for interested investors through H.C. Wainwright representatives. A live webcast will be available online, with a replay accessible on Theravance's website for 30 days following the event.

News Market Reaction

-0.29%

1 alert

-0.29% News Effect

On the day this news was published, TBPH declined 0.29%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, Sept. 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.

Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9 at 1:30 PM EDT (10:30 AM PDT / 6:30 PM IST).

Management will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.

A live webcast of the event may be accessed here or on the "Events and Presentation" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma 

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543498.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma (TBPH) presenting at the H.C. Wainwright Conference?

Theravance Biopharma's CEO Rick Winningham will participate in a Fireside Chat on Tuesday, September 9, 2025, at 1:30 PM EDT.

How can investors access Theravance Biopharma's H.C. Wainwright Conference presentation?

Investors can access the presentation through a live webcast on Theravance's website under the Investors section, with a replay available for 30 days.

How can investors schedule meetings with Theravance Biopharma management at the H.C. Wainwright Conference?

Interested investors should contact their H.C. Wainwright representative to request an in-person meeting with management.

Who will represent Theravance Biopharma at the H.C. Wainwright Conference?

Rick Winningham, the CEO of Theravance Biopharma, will represent the company at the conference.